Viking Therapeutics, Inc. Income Statement

Income Statement Dec2014 Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating items
Amortization - Intangibles 0.56M0.89M1.79M1.28M0.40M
Research & Development 22.22M6.97M9.00M13.74M19.04M23.56M31.93M44.98M54.23M63.81M101.64M
Selling, General & Administrative 1.24M5.03M4.85M5.33M7.12M9.13M10.73M10.70M16.12M37.02M49.28M
Operating Expenses 23.47M12.00M13.85M19.07M26.16M32.69M42.66M55.68M70.36M100.83M150.92M
Operating Income -23.47M-12.00M-13.85M-19.07M-26.16M-32.69M-42.66M-55.68M-70.36M-100.83M-150.92M
EBIT -23.47M-12.00M-13.85M-19.07M-26.16M-32.69M-42.66M-55.68M-70.36M-100.83M-150.92M
Non-operating items
Interest & Investment Income -0.07M-0.09M-0.02M0.00M3.24M7.05M3.23M0.70M1.59M15.02M40.94M
Other Non Operating Income 1.58M-11.41M-0.88M-1.51M4.10M6.91M3.17M0.69M1.49M14.93M40.96M
Non Operating Income 1.58M-11.41M-0.88M-1.51M4.10M6.91M3.17M0.69M1.49M14.93M40.96M
Net income details
EBT -23.54M-12.09M-13.87M-19.07M-22.93M-25.64M-39.43M-54.98M-68.77M-85.81M-109.98M
Profit After Tax -21.88M-23.40M-14.73M-20.58M-22.06M-25.78M-39.49M-54.99M-68.87M-85.89M-109.96M
Income from Continuing Operations -23.54M-12.09M-13.87M-19.07M-22.93M-25.64M-39.43M-54.98M-68.77M-85.81M-109.98M
Consolidated Net Income -23.54M-12.09M-13.87M-19.07M-22.93M-25.64M-39.43M-54.98M-68.77M-85.81M-109.98M
Income towards Parent Company -23.54M-12.09M-13.87M-19.07M-22.93M-25.64M-39.43M-54.98M-68.77M-85.81M-109.98M
Net Income towards Common Stockholders -23.54M-12.09M-13.87M-19.07M-22.93M-25.64M-39.43M-54.98M-68.77M-85.81M-109.98M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 8.65M9.68M20.17M28.50M71.46M72.26M72.95M78.23M76.69M100.03M111.44M
EBITDA -21.88M-23.41M-14.73M-20.59M-22.47M-25.34M-39.56M-55.48M-69.42M-85.18M-110.36M
Shares Outstanding 6.00M9.68M20.82M35.82M71.74M72.41M73.22M78.25M78.26M100.11M111.57M